Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis – Clinical Implications in the Treatment of Patients with Type 2 Diabetes
Open Access
- 1 January 2016
- journal article
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Endocrinology
- Vol. 12 (1), 33-34
- https://doi.org/10.17925/EE.2016.12.01.33
Abstract
The use of sodium-glucose cotransporter 2 inhibitors is associated with an increased risk of diabetic ketoacidosis. This risk has been reported in particular in off-label use of these agents in type 1 diabetes, but reports of risks in type 2 diabetes patients also exist. In type 2 diabetes ketoacidosis is rare and is present particularly in patients who have undergone prolonged starvation, serious infection, alcohol abuse or surgery. The pleiotropic advantages of sodium-glucose cotransporter 2 inhibitors do not outweigh the risk for a diabetic ketoacidosis, but caution is warranted.Keywords
This publication has 12 references indexed in Scilit:
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2015
- Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusCardiovascular Diabetology, 2015
- Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical ProgramDiabetes Care, 2015
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretionNature Medicine, 2015
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes MellitusDrugs, 2014
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysisEuropean Journal of Clinical Pharmacology, 2014
- Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta‐analysisDiabetes, Obesity and Metabolism, 2014
- Sodium Glucose Transport 2 (SGLT2) Inhibition Decreases Glomerular HyperfiltrationJournal of the American College of Cardiology, 2014
- Efficacy and safety of sodium glucose co‐transport‐2 inhibitors in type 2 diabetes: a meta‐analysis of randomized clinical trialsDiabetes, Obesity and Metabolism, 2013
- Renal Tubular Reabsorption of Acetoacetate, Inorganic Sulfate and Inorganic Phosphate in the Dog as Affected by Glucose and PhlorizinAmerican Journal of Physiology-Legacy Content, 1955